1. Home
  2. EMF vs ARMP Comparison

EMF vs ARMP Comparison

Compare EMF & ARMP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Templeton Emerging Markets Fund

EMF

Templeton Emerging Markets Fund

HOLD

Current Price

$23.27

Market Cap

253.7M

Sector

Finance

ML Signal

HOLD

Logo Armata Pharmaceuticals Inc.

ARMP

Armata Pharmaceuticals Inc.

HOLD

Current Price

$8.10

Market Cap

295.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
EMF
ARMP
Founded
1987
N/A
Country
United States
United States
Employees
N/A
N/A
Industry
Finance/Investors Services
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
253.7M
295.5M
IPO Year
N/A
1996

Fundamental Metrics

Financial Performance
Metric
EMF
ARMP
Price
$23.27
$8.10
Analyst Decision
Strong Buy
Analyst Count
0
2
Target Price
N/A
$15.00
AVG Volume (30 Days)
42.7K
69.0K
Earning Date
01-01-0001
05-07-2026
Dividend Yield
6.16%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$13.44
$1.74
52 Week High
$23.40
$14.98

Technical Indicators

Market Signals
Indicator
EMF
ARMP
Relative Strength Index (RSI) 73.05 42.01
Support Level $16.24 $7.22
Resistance Level N/A $8.40
Average True Range (ATR) 0.65 0.94
MACD 0.05 0.02
Stochastic Oscillator 80.20 49.17

Price Performance

Historical Comparison
EMF
ARMP

About EMF Templeton Emerging Markets Fund

Templeton Emerging Markets Fund is a closed-end management investment company that seeks long-term capital appreciation by investing mainly in emerging country equity securities under normal market conditions. It invests across various sectors, including Pharmaceuticals, Beverages, Broadline Retail, Metals & Mining, Banks, Food Products, Semiconductors & Semiconductor Equipment, Insurance, Entertainment, and others.

About ARMP Armata Pharmaceuticals Inc.

Armata Pharmaceuticals Inc is a late clinical-stage biotechnology company focused on the development of high-purity and potent, pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using proprietary bacteriophage-based technology. It has completed three Phase 2 clinical trials to date. The Company operates and manages its business as one reportable operating segment, which is the business of developing pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat acute and chronic bacterial infections using its proprietary bacteriophage-based technology.

Share on Social Networks: